OBJECTIVES:To inform strategic decisions on respiratory syncytial virus (RSV) vaccine development and identify critical endpoints likely to drive the vaccine's medical and economic impact. DESIGN:A decision-analysis model populated using healthcare utilization data and costs from the literature; vaccine efficacy and duration based on assumptions. SETTING:Vaccination in the physician office setting in the USA. PARTICIPANTS:A hypothetical cohort of newborn infants. INTERVENTION:Vaccination of children at low and high risk of respiratory sequelae with a theoretical RSV vaccine vs palivizumab prophylaxis for children at high risk. OUTCOME MEASURES:Medical and economic value of RSV vaccination, including cost per quality adjusted life-year (QALY) gained. RESULTS:Using base-case assumptions (efficacy 50% at birth; half-life 12 months), RSV vaccination would prevent 23,069 hospitalizations and 66 deaths per vaccinated birth cohort in the USA. Excluding vaccination costs, direct medical costs for RSV would reduce by $236 million, and income and productivity losses by $134 million. Assuming a vaccine cost per course similar to Rotarix® in the USA ($232 including administration fees), the cost per QALY gained would be $93,401 (95% CI: $65,815-$126,060) from the healthcare system perspective and $65,115 (95% CI: $41,003-$93,679) from the societal perspective. The net cost (healthcare system perspective) per life-year saved would be $216,120 (95% CI: $161,184-$263,981); the cost per hospitalization averted would be $19,172 (95% CI: $14,679-$22,093). Aside from efficacy, the vaccine's impact is sensitive to the start of protective immunity and the duration of protection. CONCLUSIONS:Development of an RSV vaccine would substantially reduce inpatient hospitalizations and outpatient visits. It would also have an impact on infant mortality. To demonstrate the full medical and economic value of the vaccine, appropriate endpoints or endpoint surrogates for hospitalization, mortality, and total case reductions should be collected during vaccine development.

译文

目的:为呼吸道合胞病毒(RSV)疫苗的开发提供战略决策,并确定可能推动该疫苗的医疗和经济影响的关键终点。
设计:使用医疗保健利用率数据和文献中的成本填充的决策分析模型;基于假设的疫苗效力和持续时间。
地点:在美国的医师办公室进行疫苗接种。
参与者:新生婴儿的假想队列。
干预:理论上RSV疫苗对低和高危呼吸系统后遗症的儿童进行疫苗接种,对高危儿童进行帕利珠单抗预防。
观察指标:RSV疫苗的医学和经济价值,包括获得的每质量调整生命年(QALY)的成本。
结果:使用基本病例假设(出生时效率为50%;半衰期为12个月),在美国,RSV疫苗接种可预防23,069例住院和每例接种出生队列66例死亡。不包括疫苗接种费用,RSV的直接医疗费用将减少2.36亿美元,收入和生产力损失将减少1.34亿美元。假设每个疗程的疫苗费用与美国的Rotarix®相似(232美元,包括管理费),那么从医疗保健系统的角度来看,每个QALY的费用将为93,401美元(95%CI:65,815-126,060美元),以及65,115美元(95%CI:41,003美元) -$ 93,679)。每个生命年节省的净成本(从医疗保健系统的角度来看)将为$ 216,120(95%CI:$ 161,184- $ 263,981);避免的每次住院费用为$ 19,172(95%CI:$ 14,679- $ 22,093)。除了功效外,疫苗的影响还对保护性免疫的开始以及保护的持续时间敏感。
结论:RSV疫苗的开发将大大减少住院病人的住院和门诊病人的次数。这也将对婴儿死亡率产生影响。为证明疫苗的全部医学和经济价值,应在疫苗开发过程中收集住院,死亡率和总病例数减少的适当终点或终点替代指标。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录